Join our fast growing team

MDoutlook is continuing its fast growth path. To support our growth, and overall client services and experience, we are keen to add a Manager, Strategic Development to our team at our headquarters in greater Atlanta.

Playing a vital supportive role initially within our business, we look to expand the role quickly to take on greater responsibility within our strategic development team and be exposed to working across our business and with clients. The ideal candidate will be dynamic, energetic and hungry for success. Learn more about the Manager Strategic Development May 2019 here.

If you are interested and qualify for this exciting and demanding position in a great work environment, submit your resume and cover letter directly to our Human Resources group. Solicitation by recruiters will not be considered.

Biomarkers are valued but 1 in 3 oncologists want improvement

Biomarkers are embraced by oncologists as an important tool in their arsenal to treat cancer. They enable a more personalized approach to treatment by identifying patients who are likely to respond to specific immunotherapies and yet oncologists want pharma to do more.

In our 2019 Leadership study, we asked oncologists to reveal their most wanted areas for improvement in ImmunoOncology (IO) where pharma companies should focus their efforts. Their priority list revealed, 1 in 3 oncologists wanted better patient selection through biomarkers. This was among the top 3 priorities with financial impact and access to IO therapies. Our analysis revealed that 35% of European based oncologists want pharma to improve biomarkers compared to 29% of US based colleagues.

Oncologists want to improve patient selection through biomarkers
Click on image to enlarge

While IO therapies can offer tremendous improvement for patients, their response rate to a specific tumor can be as low as 20-30%. The individual gene activity within a cancer is an important cause underlying these varied responses. Certain genes in progressing tumors are activated by immunotherapy and this activity can dampen the immune cell response. We are now seeing combination therapies (using two different IO therapies) entering clinical practice with leading oncologists, and genetic profiling will become even more important in aiding the usage of combining different IO therapies. Oncologist intent to utilize and actual usage of genetic profiling is corroborated in many onco-diagnostics focused MDoutlook research.

Given the benefits of genomic profiling, the MDoutlook team is not surprised that specialized companies such as Foundation Medicine (FMI) have attracted the attention of oncology heavy weights such as Roche. In 2018, Roche completed its acquisition of FMI and is now using their technology to identify molecular alterations in a patient’s cancer. In patients with a high level of mutations, they may only need one IO drug while those with lower levels get a combination therapy. We have extensively studied the area of companion diagnostics and expect more integration beyond the ubiquitous licensing arrangements.

These improved predictions can also help oncologists to adjust their treatment approach and ultimately improve outcomes for patients. Based on late 2018 research with leading oncologists, we expect significant research and developments with respect to combining immune-oncology drugs in relevant patients to boost overall and continued response. Biomarkers are highly valued by oncologists and together with clinical factors (overall survival, quality of life), label and availability of biomarkers have the greatest impact on IO treatment selection.

Click on image to enlarge
Click on image to enlarge

This showcases an opportunity for pharma and represents one of many areas where MDoutlook offer significant research experience through targeted conference research and use of ONCpulse™ in accessing the world’s largest community of oncologists and experts.

As a trusted partner in oncology, MDoutlook is uniquely placed to help you with precision intelligence and ThoughtLeader engagement ahead of the conference season. Let’s take your next step together.

We look forward to meeting you at the American Society of Clinical Oncology (ASCO) annual meeting (May 31 – June 4) in Chicago and the European Hematology Association (EHA) annual meeting (June 13 – 17) in Amsterdam.

For further discussion or to arrange a meeting, please contact [email protected] or call +1 404.496.4136.

If you wish to be included in the distribution of the 2019 Leadership study, please click here.

Oncologists have no clear leader in pharma engagement solutions

Oncologists have no clear leader when asked about the supportive services and tools provided to them by pharmaceutical companies. Our 2019 Leadership study in ImmunoOncology (IO) explored oncologists’ views across multiple engagement channels ranging from digital support solutions (e.g. apps) to more traditional activities such as educational learning.

HealthCare Provider (HCP) engagement profits from activities that are collaborative in their nature. Providing educational support to both staff and oncologists was appreciated by the surveyed oncologists and contributes to their perception of corporate leadership.

While there was no overall leader in HCP engagement, BMS, Merck and Roche formed the top three companies in our survey, yet collectively not even reaching the 50% mark of all responses.

Oncologists have no clear leader in professional solutions
Click to enlarge image

Similar to our findings in patient support programs, over a quarter of oncologists selected “None” tying it in pole position with BMS (26%). This suggests poor awareness, choice or possibly some dissatisfaction with HCP engagement activities offered by pharmaceutical companies.

To be successful, firms need to provide differentiated solutions that are pertinent to oncologists, offering value and optimization in their work with patients.

Utilizing multiple activities to support the varying needs of oncologists can increase customer interactions and these can be tailored using specialized functions such as medical science liaison (MSL). Given growth of different treatment options in oncology, MSLs are viewed favorably as a trusted resource for unbiased, non-promotional information about treatments.

Our latest findings are a timely input as most companies start their brand planning activities across marketing, medical affairs and other teams to drive successful leadership in the eyes of oncologists.

About the study

The 2019 Leadership Study was conducted with 100 oncologists across US and EU using MDoutlook’s proprietary ONCpulse™ service.

The research objectives were to:

  • Define the meaning of “corporate leadership” to the oncology community
  • Reveal the leaders in oncology and IO and to compare / contrast how companies are evaluated by oncologists
  • Assess current drivers & barriers to IO treatment use and identify what oncologists would like to see improved by corporate leaders in the IO space

Please contact us if you wish to be included in the distribution of the study.